Fulcrum Therapeutics Stock (NASDAQ: FULC)

Fulcrum Therapeutics (NASDAQ:FULC) Stock, Quote.Headers.trade-ideas

Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Biotech

Earnings

Earnings Beats

News

Penny Stocks

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

General

FULC

ILMN

KRYS

VNDA

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that the FDA issued a complete response letter to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis.

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

Large Cap

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) plunged 61.1% on Sept.

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Equities

Eurozone

Commodities

Intraday Update

MODV

NTGR

ONCT

SMFL

Dow Surges Over 100 Points; ModivCare Shares Plummet

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics Inc

WIIM

Trump Media & Technology shares are trading lower possibly amid the expiration of the lockup period that prevents large shareholders, such as Donald Trump, from selling stocks. Also, Donald Trump rejected a second debate with Vice President Harris.

<p>Truist Securities  analyst William Stein   downgrades Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) from Buy to Hold and lowers the price target from $89 to $80.</p>


Downgrades

Price Target

MCHP

Truist Securities Downgrades Microchip Technology to Hold, Lowers Price Target to $80

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Israeli Military Says Warning Sirens Sound In The Shomron Area Of The Northern West Bank

Oil is trading higher amid Israel-Hezbollah tensions in Lebanon, which has caused supply uncertainty.

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Neutral and maintains $170 price target.</p>


Reiteration

GDDY

Cantor Fitzgerald Reiterates Neutral on GoDaddy, Maintains $170 Price Target

AMPX

Amprius Technologies shares are trading higher after the company announced it received two contracts worth over $20 million to supply 40 ah high-performance cells for light EV applications.

<p>Truist Securities  analyst William Stein   downgrades Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) from Buy to Hold and lowers the price target from $266 to $233.</p>


Truist Securities Downgrades Analog Devices to Hold, Lowers Price Target to $233

KAVL

Kaival Brands Innovations Group Shares Resumed Trade

<p>JP Morgan  analyst Rodolfo Angele   maintains Vale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>) with a Overweight and lowers the price target from $16.5 to $15.</p>


VALE

JP Morgan Maintains Overweight on Vale, Lowers Price Target to $15

<p>Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 70% of traders were bullish, while 10% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $112,088, and 8 were calls, valued at $304,824.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $175.0 for Novo Nordisk, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Novo Nordisk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Novo Nordisk's significant trades, within a strike price range of $120.0 to $175.0, over the past month.</p>
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100972_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$120.00</td>
<td>$86.0K</td>
<td>1.9K</td>
<td style="text-align: right;">109</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.75</td>
<td>$8.55</td>
<td>$8.7</td>
<td>$135.00</td>
<td>$52.2K</td>
<td>750</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.1</td>
<td>$9.0</td>
<td>$9.1</td>
<td>$125.00</td>
<td>$45.5K</td>
<td>309</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$1.25</td>
<td>$1.22</td>
<td>$1.25</td>
<td>$175.00</td>
<td>$45.1K</td>
<td>292</td>
<td style="text-align: right;">363</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$4.7</td>
<td>$4.55</td>
<td>$4.65</td>
<td>$130.00</td>
<td>$37.2K</td>
<td>619</td>
<td style="text-align: right;">166</td>
</tr>
</tbody>
</table>
</p>
<h3>About Novo Nordisk</h3>
<p>With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.</p>
<p>After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>Trading volume stands at 1,564,079, with NVO's price down by -3.33%, positioned at $123.26.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 44 days.</li>
</ul>
<h3>What Analysts Are Saying About Novo Nordisk</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $160.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $160.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Novo Nordisk's Options: A Look at What the Big Money is Thinking

<p>High-rolling investors have positioned themselves bullish on Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SE often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Sea. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 60% bullish and 30% bearish. Among all the options we identified, there was one put, amounting to $28,224, and 9 calls, totaling $403,455.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $120.0 for Sea during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Sea's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Sea's whale trades within a strike price range from $40.0 to $120.0 in the last 30 days. </p>
<h3>Sea Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100967_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$1.55</td>
<td>$1.52</td>
<td>$1.55</td>
<td>$90.00</td>
<td>$72.2K</td>
<td>2.4K</td>
<td style="text-align: right;">389</td>
</tr>
<tr>
<td>SE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.05</td>
<td>$6.0</td>
<td>$6.05</td>
<td>$120.00</td>
<td>$59.2K</td>
<td>87</td>
<td style="text-align: right;">98</td>
</tr>
<tr>
<td>SE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$53.5</td>
<td>$53.0</td>
<td>$53.0</td>
<td>$40.00</td>
<td>$53.0K</td>
<td>627</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>SE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$9.1</td>
<td>$8.75</td>
<td>$8.99</td>
<td>$85.00</td>
<td>$44.9K</td>
<td>748</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>SE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$9.0</td>
<td>$8.75</td>
<td>$8.9</td>
<td>$85.00</td>
<td>$44.5K</td>
<td>748</td>
<td style="text-align: right;">104</td>
</tr>
</tbody>
</table>
</p>
<h3>About Sea</h3>
<p>Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value and number of transactions. Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce, which is now the main growth driver. Shopee is a hybrid C2C and B2C marketplace platform operating in eight core markets. Indonesia accounts for 35% of GMV, with the rest split mainly among Taiwan, Vietnam, Thailand, Malaysia, and the Philippines. For Garena, Free Fire was the most downloaded game in January 2022 and accounted for 74% of gaming revenue in 2021. Sea's third business, SeaMoney, provides lending and we foresee it becoming a larger part of the entire busines in the long term as its loan book has grown to $3.5 billion in 2024.</p>
<p>Following our analysis of the options activities associated with Sea, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Sea</h3>
<ul>
<li>Trading volume stands at 1,609,356, with SE's price up by 3.98%, positioned at $89.12.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 50 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Sea with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Sea's Options Frenzy: What You Need to Know

Lebanon Hezbollah Says It Targeted Military Base In Northern Israel With Dozens Of Missiles

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Core Scientific</strong>.</p>
<p>Looking at options history for Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 18% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $357,725 and 7, calls, for a total amount of $463,780.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.0 to $15.0 for Core Scientific during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Core Scientific's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Core Scientific's whale activity within a strike price range from $7.0 to $15.0 in the last 30 days. </p>
<h3>Core Scientific 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727100962_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.4</td>
<td>$0.3</td>
<td>$0.4</td>
<td>$14.00</td>
<td>$200.0K</td>
<td>5.5K</td>
<td>5.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$0.25</td>
<td>$0.2</td>
<td>$0.25</td>
<td>$11.50</td>
<td>$113.9K</td>
<td>75</td>
<td>4.5K</td>
</tr>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$15.00</td>
<td>$105.0K</td>
<td>25</td>
<td>300</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$12.00</td>
<td>$99.7K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$0.8</td>
<td>$0.7</td>
<td>$0.75</td>
<td>$11.00</td>
<td>$75.0K</td>
<td>35</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Core Scientific</h3>
<p>Core Scientific Inc is engaged in Blockchain and AI Infrastructure, Digital Asset Self-Mining, Premium Hosting, Blockchain Technology, and Artificial Intelligence related services. The business operates in two segments being; Equipment Sales and Hosting which consists of blockchain infrastructure, third-party hosting business and equipment sales to customers. Mining segment consists of digital asset mining for its account. The blockchain business generates revenue from the sale of consumption-based contracts and by providing hosting services. The digital asset mining segment earns revenue from operating a firm's owned computer equipment as part of a pool of users that process transactions conducted on one or more blockchain networks. In exchange, it receives digital currency assets.</p>
<p>After a thorough review of the options trading surrounding Core Scientific, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Core Scientific</h3>
<ul>
<li>Currently trading with a volume of 1,726,806, the CORZ's price is up by 3.17%, now at $12.36. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 51 days.</li>
</ul>
<h3>Expert Opinions on Core Scientific</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $17.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $20.<br />
&#x2A; Reflecting concerns, an analyst from Bernstein lowers its rating to Outperform with a new price target of $17.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $16.<br />
&#x2A; An analyst from Canaccord Genuity has revised its rating downward to Buy, adjusting the price target to $16. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Core Scientific options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Core Scientific, Inc. - Class A Common Stock

CORZ

Smart Money Is Betting Big In CORZ Options

Novo Nordisk shares are trading lower amid reports of weight loss drug pricing criticism from US Senator Bernie Sanders.

<p>Microsoft co-founder and one of the world&#8217;s most prominent tech visionaries, Bill Gates, is turning his attention toward a <a href="https://www.benzinga.com/topic/artificial-intelligence">new type of technology</a>.<br /><strong><br /></strong>In an interview with CNBC, Gates said that if he were to launch a startup today, he would leave his software roots behind and focus squarely on artificial intelligence (AI).</p>
<p>"Today, somebody could raise billions of dollars for a new AI company [that's just] a few sketch ideas," Gates told CNBC, reflecting AI&#8217;s fervor. So far this year, startups in the field have attracted more than $26 billion in investments, according to CNBC citing data from PitchBook.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"><strong> </strong><strong>now harbor a huge investment opportunity at just $500.</strong></a></strong></li>
<li><strong>General Motors and other leaders revealed to be<a href="https://www.benzinga.com/money/energyx"><strong> </strong><strong>investing in this revolutionary lithium start-up — allowing easy entry by launching at just $9.50/share with a $1,000 minimum.</strong></a></strong></li>
</ul>
<p>If Microsoft&#8217;s co-founder were to embark on the venture, Gates said his AI company would aim to compete with tech giants like Nvidia, Google and OpenAI or find an area where AI could deliver unique value.<br /><br />&#8220;To really stand out as a small company, you have to pick something you're going to do uniquely," Gates told CNBC.</p>
<p>His shift in focus from software to AI mirrors a changing tech landscape. CNBC noted that when Microsoft was founded in 1976, Gates and co-founder Paul Allen were among the few who envisioned a future where computers would be part of everyday life.</p>
<p><strong>Trending: Groundbreaking trading app with a ‘Buy-Now-Pay-Later' feature for stocks tackles the $644 billion margin lending market –<a href="https://www.benzinga.com/money/wolfpack"><strong> </strong><strong>here&#8217;s how to get equity in it with just $500</strong></a></strong></p>
<p>"I was lucky that my belief in software made me unique," Gates said. "Just believing in AI, that's not unique. So I would have to develop some unique view of how you design AI systems – something that other people didn't get."</p>
<p>The billionaire said that entering the AI space at this stage comes with its own set of challenges. With foundational technologies already being developed by well-funded companies, new entrants may struggle to make an impact. Gates told entrepreneurs to focus on how AI could address specific business needs or improve daily life – whether by automating expensive tasks or generating strategic insights with broader applications.</p>
<p><strong>Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"><strong>These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</strong></a></strong></p>
<p>At 68, Gates' priorities have shifted. While he once measured success by Microsoft&#8217;s growth, today he is more focused on adding value to the world, <a href="https://www.benzinga.com/general/entertainment/22/07/28069438/bill-gates-doesnt-want-to-be-rich-anymore-i-will-move-down-and-eventually-off-of-the-list-5">particularly through his philanthropic work</a> with the Bill &amp; Melinda Gates Foundation and his clean-energy investment firm, Breakthrough Energy.<br /></p>
<p>He has been encouraging younger minds at Microsoft, OpenAI and other tech companies to push the boundaries of AI, telling them, "Because you're taking a fresher look at this than I am, and that's your fantastic opportunity."</p>
<p>Just as his early faith in personal computing was prophetic, Gates' focus on AI may again prove to be a bellwether for the future of technology.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Elon Musk&#8217;s secret mansion in Austin revealed through court filings.<a href="https://www.benzinga.com/money/elon-musk-secret-mansion-austin-nada"><strong> </strong><strong>Here&#8217;s how to invest in the city&#8217;s growth before prices go back up.</strong></a></strong></li>
<li><strong>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"><strong> you can become part of the next big real estate boom today.</strong></a></strong></li>
</ul>


Startups

Bill Gates Says If He Started Microsoft Today, He'd Focus On This Industry Instead

Federal Reserve

Fed's Goolsbee Sees 'Many More Rate Cuts' Over Next Year; Comfortable With Fed's 50 BPs Rate Cut, Shows Fed Is Focused On Risks To Employment, Not Just Inflation; Inflation Is 'Way Down' From Peak, Labor Market Is At Full Employment; Keeping Rates At Decade-High Does Not Make Sense When You Want Things To Stay Where They Are; To Reach Soft Landing, Cannot Be Behind The Curve; Rates Must Come Down Significantly

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and maintains $130 price target.</p>


EXPE

Cantor Fitzgerald Reiterates Neutral on Expedia Group, Maintains $130 Price Target

<p>JP Morgan  analyst Tami Zakaria   maintains United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) with a Overweight and raises the price target from $780 to $940.</p>


JP Morgan Maintains Overweight on United Rentals, Raises Price Target to $940

<p>Cantor Fitzgerald  analyst Deepak Mathivanan   reiterates Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Neutral and maintains $50 price target.</p>


ETSY

Cantor Fitzgerald Reiterates Neutral on Etsy, Maintains $50 Price Target

<p><a href="https://press.aboutamazon.com/2024/9/amazon-and-aws-expand-partnership-with-slb-to-accelerate-digital-and-decarbonization" title="https://press.aboutamazon.com/2024/9/amazon-and-aws-expand-partnership-with-slb-to-accelerate-digital-and-decarbonization">https://press.aboutamazon.com/2024/9/amazon-and-aws-expand-partnership-with-slb-to-accelerate-digital-and-decarbonization</a></p>


AMZN

Amazon And AWS Expand Partnership With SLB Through Multi-Year Agreement To Explore Low Carbon Technology Deployment And Accelerate Digital Decarbonization

<strong><i>The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read…</i></strong><br><br><p>The biotech industry is currently seeing a heightened demand for high-quality healthcare, innovative treatments, and advanced solutions, largely due to an aging population and escalating healthcare requirements. Given its rapid pace of innovation and promising growth potential, investing in select biotech stocks could be wise.</p>
<p>Amid this backdrop, fundamentally robust biotech stocks such as Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>), BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), and Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>) could offer significant return potential owing to their dominance in high-demand areas and transformative treatments.</p>
<p>The biotechnology industry is experiencing rapid growth due to rising demands for personalized medicine, tailored treatments, and the approval of new drugs by the Food and Drug Administration (FDA).</p>
<p>This trend is highlighted in a survey conducted by GlobalData, which reveals that 44% of healthcare industry professionals globally are <a href="https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/">optimistic or extremely optimistic</a> about the recovery of biotech funding in the next twelve months.</p>
<p>Incorporating Generative AI (GenAI) into biotechnology subjects is also revolutionizing the industry by enabling companies to derive valuable consumer insights, craft precise marketing strategies, and redefine healthcare engagements.</p>
<p>According to the McKinsey Global Institute, the integration of GenAI is anticipated to contribute an annual economic value of <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-ai-in-commercial-life-sciences">$60 billion to $110 billion</a> for pharmaceutical and medtech firms.</p>
<p>Furthermore, according to a report by Precedence Research, the U.S. biotechnology market was valued at $246.18 billion in 2023 and is expected to expand at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size,with%20revenue%20share%20in%202023.">a CAGR of 11.6%</a>, reaching approximately $830.31 trillion by 2034.</p>
<p>Considering these factors, let's discuss the fundamentals of three high-potential <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks under $10, starting with #3.</p>
<p><strong>Stock #3: Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>)</strong></p>
<p>FULC is a clinical-stage biopharmaceutical company focused on treating genetically defined rare diseases. Its clinical product candidates, losmapimod and FTX-6058, are developed for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease (SCD), respectively.</p>
<p>On May 13, FULC announced its <a href="https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-enters-collaboration-and-license-agreement">collaboration and license agreement</a> with Sanofi (<a href="https://stocknews.com/stock/SNY/">SNY</a>) for the development and commercialization of losmapimod, for the treatment of FSHD. SNY obtains exclusive commercialization rights for losmapimod outside of the United States under the agreement.</p>
<p>With the help of SNY's global reach, it could become easier for FULC to expand its pipeline and grab a stronger market presence in the FSHD treatment zone.</p>
<p>For the fiscal 2024 second quarter that ended on June 30, 2024, FULC's collaboration revenue increased significantly year-over-year to $80 million. The company's <a href="https://www.investopedia.com/terms/i/ifo.asp">income from operations</a> came in at $52.49 million, compared to a loss of $27.29 million in the previous year's quarter.</p>
<p>Also, its net income and net income per share were reported to be $55.41 million and $0.87, compared to a net loss and net loss per share of $23.78 million and $0.38, respectively.</p>
<p>Analysts expect FULC's revenue to increase 707.3% year-over-year to $7.03 million for the fiscal fourth quarter ending December 2024. Meanwhile, the consensus revenue estimate of $86.56 million for the fiscal year ending December 2024 reflects a significant year-over-year rise.</p>
<p>FULC's stock has gained 30.2% over the past three months and 96.4% over the past nine months to close the last trading session at $9.39.</p>
<p>FULC's bright outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.</p>
<p>FULC has a B grade for Value and Quality. It is ranked #26 among 341 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.</p>
<p><a href="https://stocknews.com/stock/FULC/">Click here</a> to access FULC's ratings for Growth, Stability, Momentum, and Sentiment.</p>
<p><strong>Stock #2: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)</strong></p>
<p>BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics for rare diseases. Its products include ORLADEYO for hereditary angioedema prevention and RAPIVAB for acute uncomplicated influenza treatment in the United States.</p>
<p>On July 9, BCRX announced that its <a href="https://ir.biocryst.com/news-releases/news-release-details/orladeyor-berotralstat-approved-peru">oral, once-daily medication ORLADEYO&#xAE;</a> received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru. The approval allows ORLADEYO&#xAE; to be used for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.</p>
<p>Moreover, the approval in Peru adds to BCRX's established presence in the pan-Latin America region, following previous approvals in Chile, Argentina, Brazil, and Mexico. It signifies a significant milestone for BCRX, expanding its market and potentially attracting more customers seeking treatment for HAE.</p>
<p>BCRX's total revenues increased 32.5% year-over-year to $109.33 million for the fiscal 2024 second quarter that ended June 30, 2024.  Its adjusted income from operations also increased to $21.93 million compared to a loss of $7.86 million in the previous year's quarter.</p>
<p>In addition, as of June 30, 2024, BCRX's cash, cash equivalents and investments amounted to $336.34 million while total assets came in at $472.42 million.</p>
<p>BCRX's consensus revenue estimate of $113.89 million for the fiscal third quarter ending September 2024 reflects a year-over-year increase of 31.3%. Also, for the fiscal fourth quarter ending December 2024, BCRX's revenue is expected to increase by 26% from the prior year to $117.67 million.</p>
<p>In addition, BCRX has topped the consensus revenue estimates in all of the trailing four quarters, which is impressive.</p>
<p>Shares of BCRX have surged 31.3% in the past three months and 45.8% in the past nine months to close the last trading session at $8.05.</p>
<p>BCRX's robust outlook is reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.</p>
<p>BCRX has a B grade for Growth, Sentiment, Value, and Quality. It has ranked #17 out of 341 stocks in the Biotech industry.</p>
<p><a href="https://stocknews.com/stock/BCRX/">Click here</a> to access BCRX's ratings for Stability and Momentum.</p>
<p><strong>Stock #1: Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>)</strong></p>
<p>DTIL is an innovative gene editing company specializing in developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. The company's focus is on advancing gene edits and transformative treatments within these critical medical fields.</p>
<p>On August 9, DTIL announced <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-investigational-new-drug">U.S. Food and Drug Administration's (FDA) approval</a> for its partner TG Therapeutics, Inc. (<a href="https://stocknews.com/stock/TGTX/">TGTX</a>) to commence Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for its Investigational New Drug (IND) Application for progressive forms of multiple sclerosis (MS).</p>
<p>As the company receives approvals for its drugs in the auto-immune disease treatment market, it ensures a stronger market presence and presents better growth prospects.</p>
<p>On July 1, DTIL announced its addition to the <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-its-addition-russell-microcapr">Russell Microcap&#xAE; Index</a>, a key benchmark utilized by investment managers and institutional investors for index funds. The inclusion could lead to heightened visibility globally, attracting potential investors and fostering further growth opportunities for the company.</p>
<div class="flex-1 overflow-hidden">
<div class="h-full">
<div class="react-scroll-to-bottom--css-ulgnp-79elbk h-full">
<div class="react-scroll-to-bottom--css-ulgnp-1n7m0yu">
<div class="flex flex-col text-sm md:pb-9">
<article class="w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]" dir="auto" data-testid="conversation-turn-17" data-scroll-anchor="true">
<div class="text-base py-[18px] px-3 md:px-4 m-auto md:px-5">
<div class="mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl">
<div class="group/conversation-turn relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex-col gap-1 md:gap-3">
<div class="flex max-w-full flex-col flex-grow">
<div class="min-h-[20px] text-message flex w-full flex-col items-end gap-2 break-words [.text-message+&amp;]:mt-5 overflow-x-auto whitespace-normal" dir="auto" data-message-author-role="assistant" data-message-id="8fe0c70b-67a1-4de1-a838-d3c1def07b65">
<div class="flex w-full flex-col gap-1 empty:hidden first:pt-[3px]">
<div class="markdown prose w-full break-words dark:prose-invert dark">
<p>For the fiscal 2024 second quarter that ended June 30, DTIL's revenue increased 152.2% year-over-year to $49.90 million. Its operating income amounted to $24.15 million compared to a loss of $3.13 million in the previous year's quarter.</p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</article>
</div>
</div>
</div>
</div>
</div>
<p>Additionally, the company's net income and net income per share came out to be $32.75 million and $4.67 compared to a net loss and loss per share of $11.89 million and $3.13, respectively.</p>
<p>Analysts project DTIL to achieve $57.40 million in revenue for the fiscal year ending December 2024, reflecting a 17.8% year-over-year increase. Additionally, the company is expected to report an EPS of $2.10 for the period. Notably, DTIL has exceeded consensus revenue estimates in three of its last four quarters.</p>
<p>DTIL's shares marginally declined intra-day close the last trading session at $9.85.</p>
<p>The stock's positive fundamentals are reflected in its POWR Ratings. DTIL has an overall rating of B, which equates to a Buy in our proprietary rating system.</p>
<p>DTIL has an A grade for Sentiment and a B grade for Value. It is ranked #16 out of 341 stocks within the same industry.</p>
<p><a href="https://stocknews.com/stock/DTIL/">Click here</a> to access DTIL's ratings for Stability, Quality, Growth, and Momentum.</p>
<p><em><strong>What To Do Next?</strong></em></p>
<p>43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.</p>
<p><strong><a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt; </a></strong></p>
<p>&nbsp;</p>

<hr />
<p>BCRX shares were trading at $8.05 per share on Tuesday morning, down $0.18 (-2.19%). Year-to-date, BCRX has gained 34.39%, versus a 18.97% rise in the benchmark S&amp;P 500 index during the same period.</p>
<hr><div style="clear:both;"></div><br><h2>About the Author: Aanchal Sugandh</h2><br><img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;"><p>Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.</p><p><a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a></p>The post <strong><a href=https://stocknews.com/news/bcrx-fulc-dtil-tgtx-sny-3-high-potential-biotech-stocks-under-10/>3 High-Potential Biotech Stocks Under $10</a></strong> appeared first on <strong><a href=https://stocknews.com/>StockNews.com</a></strong>

3 High-Potential Biotech Stocks Under $10

Fulcrum rises after BofA upgrades rating on chance of FSHD study success

Fulcrum crashes as GSK-partnered lead program fails

Stifel Nicolaus analyst Dae Gon Ha maintained a Buy rating on Fulcrum Therapeutics (FULC – Research Report) today and set a price target of $22.00....

Stifel Nicolaus Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)

Fulcrum downgraded after setback for lead program (update)

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

In a report released on September 11, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics (FULC – Research Report...

Buy Rating on Fulcrum's Losmapimod: Navigating FSHD Treatment Potential Despite Phase 2 Challenges

Fulcrum Therapeutics (FULC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein fro...

Hold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease Candidate

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024.

Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14

BCRX

CVNA

DTIL

MRNA

ORCL

ROKU

SNYNF

TGTX

ULTA

Press Releases

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate in Upcoming September Conferences

Health Care

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Fulcrum Therapeutics

Fulcrum Therapeutics (FULC) Forecast

Fulcrum Therapeutics (NASDAQ:FULC) Stock, Quote.Headers.trade-ideas